This action will protect Australians from harm and save lives. Mr Butler said todays announcement would not affect compounded medicines other than GLP-1 receptors
The pivotal Phase 2 trial (Jastreboff et al., 2023) did not stratify results by time of injection, and no head-to-head timing studies have been conducted to date
BMO Capital Markets analyst Simeon Siegel told Forbes he believes Ozempic and similar drugs have the potential to trigger greater gym usage as weight loss could lead to a widespread desire to be more fit, while Piper Sandler analyst Korinne Wolfmeyer concurred the GLP-1 popularity will probably be a tailwind for fitness stocks as people aim to maintain their weight loss
A review by ONeal et al
What the April 30 Notice Actually Says On April 30, 2026, the FDA published a Federal Register notice (Docket FDA-2018-N-3240, Federal Register document 2026-08552) proposing to exclude three GLP-1 receptor agonists from the 503B Bulks List the list of bulk drug substances for which FDA has determined there is a clinical need permitting outsourcing facility compounding from raw active pharmaceutical ingredient
However, these products often contain bioactive ingredients that can influence hormone activity, metabolism, or related systems, which means they arent appropriate for everyone
